New drug combo vs. chemotherapy for EGFR-positive advanced cancer
Part of Cancer, Skin clinical trials.
This study tests a new drug combination (SYS6010 and possibly SYH2051) compared to standard chemotherapy for advanced breast cancer and other solid tumors. It aims to see if this experimental treatment can shrink tumors and help people with EGFR-positive cancers, potentially offering a new option.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 or older.
- Your cancer must be EGFR positive (a protein on the tumor cells) as confirmed by a central lab.
- You must be able to provide a tumor tissue sample for testing.
- You should have at least one measurable tumor outside the brain that can be followed on scans.
- You should be in reasonably good health (able to carry out daily activities, with an ECOG score of 0 or 1).
- If you've had brain metastases, they must be treated and stable; active brain metastases are not allowed.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a new drug (SYS6006) combined with an existing immunotherapy (called Enlonstobart) to see if it works better than the immunotherapy alone for people with advanced solid tumors. It may help shrink or slow the growth of your cancer.
This study tests a new experimental drug (called SYS6051) in people with advanced solid tumors that have not responded to standard treatments. The goal is to find out if the drug is safe and how well it works, and it might help control your cancer.
This trial tests a combination of new drugs (HRS-8080, SHR-A2009, or others) for people with advanced breast cancer that has stopped responding to previous treatments. The goal is to see if these combinations can shrink tumors or slow the cancer's growth.
This trial tests a new targeted drug called SYS6010 against standard chemotherapy for people with advanced HER2-negative, EGFR-positive breast cancer. It aims to see if the new drug works better and is safe, and you will be randomly assigned to one of the two treatments.
This trial tests a new drug called SYS6010 compared to standard chemotherapy for people with EGFR-mutated lung cancer that has stopped responding to pill treatments. It may offer a new option if your current EGFR TKI is no longer working.
This trial tests a new drug combination (SYS6023) for advanced breast cancer that has spread or cannot be surgically removed. The treatment targets a protein called HER3, which may help stop cancer growth in patients whose cancer has progressed despite previous treatments.
Hear when a new Breast cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.